2 cancer drugs from Li Ka-shing-backed Sequencio garner global attention
Two cancer vaccines from Hong Kong-based Sequencio Therapeutics have been selected for presentation at a major US conference, as companies bet on therapies based on ribonucleic acid (RNA) to deliver breakthroughs in cancer treatment. Sequencio, a subsidiary of Li Ka-shing-backed CK Life Sciences, said on Wednesday that it will present preclinical data on cancer vaccine candidates CKLS118 and…
We haven't written up this one. SCMP Business has the full story — the link below goes straight to it.
